05.11.2024 07:00 | DXRX | Capital Markets Webinar | RNS |
04.11.2024 07:00 | DXRX | Holding(s) in Company | RNS |
30.10.2024 14:58 | DXRX | PDMR Shareholding/Share Incentive Plan | RNS |
29.10.2024 10:27 | DXRX | Board Change Update | RNS |
25.10.2024 07:00 | DXRX | Issue of Share Options/PDMR Shareholdings | RNS |
24.10.2024 12:53 | DXRX | Cancellation of Share Premium Account | RNS |
15.10.2024 07:00 | DXRX | Diaceutics Announces Key Leadership Appointment | Reach |
07.10.2024 13:19 | DXRX | Holding(s) in Company | RNS |
07.10.2024 07:00 | DXRX | Block Listing Return | RNS |
02.10.2024 13:35 | VOD, MPAC, LSC | EXECUTIVE CHANGES: Dar Global chair exits; new CFOs at Kistos, Hansard | Alliance |
02.10.2024 07:00 | DXRX | PDMR Shareholding/Share Incentive Plan | RNS |
01.10.2024 07:00 | DXRX | Board Changes | RNS |
17.09.2024 13:03 | BOOT, FRAN, TM17 | EARNINGS AND TRADING: McBride swings to profit; Headlam in the red | Alliance |
17.09.2024 07:00 | DXRX | H1 2024 Results - Continued Performance & Growth | RNS |
10.09.2024 14:34 | TRU, TM17, W7L | UK earnings, trading statements calendar - next 7 days | Alliance |
09.09.2024 07:00 | DXRX | Notice of Results & Presentations | RNS |
02.09.2024 07:00 | DXRX | Appointment of Nominated Adviser and Broker | RNS |
30.08.2024 15:45 | DXRX | PDMR Shareholding/Share Incentive Plan | RNS |
27.08.2024 19:34 | MLVN, TIME, GDP | TRADING UPDATES: Shield Therapeutics lands Canada win; RUA revenue up | Alliance |
27.08.2024 07:00 | DXRX | Diaceutics Launches Enhanced Rare-Disease Offering | RNS |
19.08.2024 11:44 | DXRX | Diaceutics to unlock new revenue with multi-million pound partnership | Alliance |
19.08.2024 07:00 | DXRX | Enterprise Partnership and Launch of PMx | RNS |
05.08.2024 07:00 | DXRX | Presenting at Canaccord Genuity Growth Conference | RNS |
29.07.2024 18:09 | DXRX | PDMR Shareholding/SIP and TVR | RNS |
23.07.2024 20:54 | DXRX | IN BRIEF: Diaceutics says Non-Executive Chair Deborah Davis resigns | Alliance |
23.07.2024 16:46 | ARBB, CRPR, HEAD | EARNINGS AND TRADING: James Cropper posts loss; Arbuthnot profit falls | Alliance |
23.07.2024 07:05 | DXRX | Board Changes | RNS |
23.07.2024 07:00 | DXRX | Revenue growth of 24% in H1 with 55% now recurring | RNS |
11.07.2024 07:00 | DXRX | Senior Management Appointments | RNS |
01.07.2024 07:00 | DXRX | PDMR Shareholding/SIP and Total Voting Rights | RNS |
24.06.2024 13:15 | DXRX | Result of AGM | RNS |
17.06.2024 15:53 | CHSS, THG, SAV | UK shareholder meetings calendar - next 7 days | Alliance |
13.06.2024 07:00 | DXRX | "Precision Medicine in Oncology " Virtual Event | Reach |
07.06.2024 10:07 | DXRX, YOU | IN BRIEF: YouGov brings Diaceutics Chair Deborah Davis onto board | Alliance |
06.06.2024 07:00 | DXRX | Diaceutics - Capital Markets Event | RNS |
29.05.2024 08:00 | DXRX | Notice of AGM and Posting of Annual Report | RNS |
28.05.2024 08:54 | IPF, DXRX, SRE | IN BRIEF: Sirius Real Estate Non-Exec Director James Peggie to resign | Alliance |
28.05.2024 07:00 | DXRX | Data to be Presented at 2024 ASCO Annual Meeting | RNS |
24.05.2024 15:01 | DXRX | PDMR Shareholding/SIP and Total Voting Rights | RNS |
24.05.2024 11:08 | GETB, MRL, ATYM | DIRECTOR DEALINGS: Michael Ashcroft ups stake in Marlowe to 16% | Alliance |
23.05.2024 07:00 | DXRX | Director / PDMR Shareholding | RNS |
21.05.2024 16:27 | WRKS, DXRX, TPT | EARNINGS AND TRADING: Topps Tiles in strategic shift as swings to loss | Alliance |
21.05.2024 07:00 | DXRX | Revenue growth of 22% & order book growth of 57% | RNS |
16.05.2024 14:32 | AREC, IKA, GILD | EARNINGS AND TRADING: Michelmersh continues with positive order intake | Alliance |
16.05.2024 07:00 | DXRX | Two New Enterprise-Wide Engagements | RNS |
14.05.2024 16:18 | SMIN, PNN, SSPG | UK earnings, trading statements calendar - next 7 days | Alliance |
14.05.2024 07:00 | DXRX | Diaceutics - Capital Markets Event | RNS |
01.05.2024 07:00 | DXRX | Notice of Results & Presentations | RNS |
30.04.2024 07:00 | DXRX | PDMR Shareholding/SIP and TVR | RNS |
09.04.2024 07:00 | DXRX | Appointment of Amie Mc Neice as VP of Marketing | RNS |
05.04.2024 13:40 | DXRX | Block Listing Return | RNS |
03.04.2024 07:00 | DXRX | PDMR Shareholding/Share Incentive Plan | RNS |
02.04.2024 19:02 | KBT, EQT, DUKE | TRADING UPDATES: Roadside shares suspended; Adnams looks for funds | Alliance |
02.04.2024 07:00 | DXRX | Director/PDMR/PCA Shareholding & TR1 | RNS |
21.03.2024 13:58 | DXRX | Diaceutics upgrades diagnositc commercialisation platform, DXRX | Alliance |
21.03.2024 07:00 | DXRX | Significant upgrade to Diaceutics' DXRX platform | Reach |
19.03.2024 07:00 | DXRX | Diaceutics forms landmark industry Forum | Reach |
07.03.2024 07:00 | DXRX | Director/PDMR Shareholding | RNS |
01.03.2024 09:00 | DXRX | PDMR Shareholding / SIP and TVR | RNS |
27.02.2024 14:18 | CDL, DXRX, UOG | TRADING UPDATES: Sondrel wins USD23 million contract | Alliance |
27.02.2024 07:00 | DXRX | Expanded lab network and data capabilities | RNS |
14.02.2024 13:52 | DXRX | IN BRIEF: Diaceutics announces new marketing partnership with KPMG | Alliance |
14.02.2024 13:00 | DXRX | Diaceutics PLC - Strategic alliance with KPMG | RNS |
05.02.2024 07:00 | DXRX | Appointment of VP, Scientific & Medical Services | Reach |
30.01.2024 11:16 | DXRX | Diaceutics maintains "momentum" for year ahead on revenue rise in 2023 | Alliance |
30.01.2024 07:00 | DXRX | Diaceutics PLC – Trading Update | RNS |
25.01.2024 13:16 | DXRX | Exercise of Warrant & Total Voting Rights | RNS |
23.01.2024 14:32 | SYNT, STEM, SSPG | UK earnings, trading statements calendar - next 7 days | Alliance |
19.01.2024 07:00 | DXRX | Diaceutics PLC – Financial Calendar Update | RNS |
29.12.2023 13:18 | DXRX | PDMR Shareholding/Share Incentive Plan | RNS |
30.11.2023 12:59 | DXRX | PDMR Shareholding/Share Incentive Plan and TVR | RNS |
30.11.2023 07:00 | DXRX | Diaceutics to attend Stifel Conference in NYC | Reach |
21.11.2023 11:13 | DXRX | Notification of Major Holdings | RNS |
31.10.2023 12:38 | DXRX | PDMR Shareholding/SIP & Total Voting Rights | RNS |
11.10.2023 13:47 | DXRX | PDMR Shareholding/Share Incentive Plan and TVR | RNS |